X-linked lymphoproliferative disease |
Classification and external resources |
ICD-10 |
D82.3 |
OMIM |
308240 300635 |
DiseasesDB |
3998 |
eMedicine |
med/1370 |
MeSH |
D008232 |
X-linked lymphoproliferative disease (also known as "Duncan's disease"[1]:86 or "Purtilo syndrome"[2]) is a lymphoproliferative disorder.[3]
Contents
- 1 Causes
- 2 Presentation
- 3 References
- 4 External links
|
Causes
XLP1
There is a mutation on the X-chromosome that has been found to be associated with a T- and NK-cell lymphoproliferative disorder. The mutation is on the long arm of the chromosome, at position 25, which is denoted as Xq25. At this position, there is a deletion in the SH2D1A gene, which codes for an SH2 domain on a signal transducing protein called SLAM-associated protein (SAP).
The term "SH2" domain stands for src-homology 2 domain, which is a three-dimensional domain structure of about 100 amino acid residues. These domains are present in many signalling proteins because they permit specific, non-covalent bonding to proteins that contain phosphotyrosines. The amino acid residues adjacent to the phosphotyrosine on the target protein are what determine the unique binding specificity.[4]
The SAP protein is important in the signalling events that activate T- and NK-cells[5] because it functions as an intracellular adapter that transduces T- and NK-cell activation. Normally, the SAP protein is expressed in the cytoplasm of T- and NK-cells, where it binds to the cytoplasmic domain of the surface receptor called signaling lymphocyte activation molecule (SLAM). This binding initiates a signal transduction pathway, which results in the modulation of IFN-γ. A deletion in the SH2D1A gene leads to a non-functional SH2 domain on the SAP protein, which means it is unable to bind to the SLAM molecule, leading to a lack of modulation of IFN-γ, causing uncontrolled cell proliferation.
XLP2
A second form is associated with XIAP.[6]
Some sources recommend classifying this condition as "X-linked familial hemophagocytic lymphohistiocytosis" instead of X-linked lymphoproliferative disease.[7]
Presentation
Strangely, in boys with X-linked lymphoproliferative disorder, there is an inability to mount an immune response to the Epstein-Barr virus (EBV),[8] which often leads to death from bone marrow failure, irreversible hepatitis, and malignant lymphoma. However, the connection between EBV and X-linked lymphoproliferative disorder is yet to be determined.[9]
Patients produce insufficient numbers of CD27 memory B cells.[10]
References
- ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- ^ http://ghr.nlm.nih.gov/condition/x-linked-lymphoproliferative-disease
- ^ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. pp. 808. ISBN 1-4160-2999-0.
- ^ Abbas, A.K and Lichtman, A.H. Cellular and Molecular Immunology. Fifth Edition. Elsevier Saunders. Philadelphia. 2005
- ^ "X-linked Lymphoproliferative Syndrome: Immunodeficiency Disorders: Merck Manual Professional". http://www.merck.com/mmpe/sec13/ch164/ch164p.html. Retrieved 2008-03-01.
- ^ Rigaud S, Fondanèche MC, Lambert N, et al. (November 2006). "XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome". Nature 444 (7115): 110–4. DOI:10.1038/nature05257. PMID 17080092.
- ^ Marsh RA, Madden L, Kitchen BJ, et al. (August 2010). "XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease". Blood 116 (7): 1079–82. DOI:10.1182/blood-2010-01-256099. PMC 2938130. PMID 20489057. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2938130.
- ^ Kumar,Vinay; Cotran, Ramzi S.; Robbins, Stanley L. (2003). Robbins Basic Pathology, 7th Edition. Philadelphia: Elsevier. pp. 418. ISBN 1-4160-2534-0.
- ^ Winter, S.S. Lymphoproliferative disorders. Emedicine. December 20, 2006. http://www.emedicine.com/ped/topic1345.htm. Accessed March 2007.
- ^ Ma CS, Pittaluga S, Avery DT, et al. (February 2006). "Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease". J. Clin. Invest. 116 (2): 322–33. DOI:10.1172/JCI25720. PMC 1332028. PMID 16424938. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1332028.
External links
- X-linked lymphoproliferative disease community
- XLP Research Trust
- GeneReview/NIH/UW entry on Lymphoproliferative Disease, X-Linked
Sex linkage: X-linked disorders
|
|
X-linked recessive
|
|
Immune |
Chronic granulomatous disease (CYBB) · Wiskott–Aldrich syndrome · X-linked severe combined immunodeficiency · X-linked agammaglobulinemia · Hyper-IgM syndrome type 1 · IPEX · X-linked lymphoproliferative disease · Properdin deficiency
|
|
Hematologic |
Haemophilia A · Haemophilia B · X-linked sideroblastic anemia
|
|
Endocrine |
Androgen insensitivity syndrome/Kennedy disease · KAL1 Kallmann syndrome · X-linked adrenal hypoplasia congenita
|
|
Metabolic |
amino acid: Ornithine transcarbamylase deficiency · Oculocerebrorenal syndrome
dyslipidemia: Adrenoleukodystrophy
carbohydrate metabolism: Glucose-6-phosphate dehydrogenase deficiency · Pyruvate dehydrogenase deficiency · Danon disease/glycogen storage disease Type IIb
lipid storage disorder: Fabry's disease
mucopolysaccharidosis: Hunter syndrome
purine-pyrimidine metabolism: Lesch–Nyhan syndrome
mineral: Menkes disease/Occipital horn syndrome
|
|
Nervous system |
X-Linked mental retardation: Coffin–Lowry syndrome · MASA syndrome · X-linked alpha thalassemia mental retardation syndrome · Siderius X-linked mental retardation syndrome
eye disorders: Color blindness (red and green, but not blue) · Ocular albinism (1) · Norrie disease · Choroideremia
other: Charcot–Marie–Tooth disease (CMTX2-3) · Pelizaeus–Merzbacher disease · SMAX2
|
|
Skin and related tissue |
Dyskeratosis congenita · Hypohidrotic ectodermal dysplasia (EDA) ·
X-linked ichthyosis · X-linked endothelial corneal dystrophy
|
|
Neuromuscular |
Becker's muscular dystrophy/Duchenne · Centronuclear myopathy (MTM1) · Conradi–Hünermann syndrome · Emery–Dreifuss muscular dystrophy 1
|
|
Urologic |
Alport syndrome · Dent's disease · X-linked nephrogenic diabetes insipidus
|
|
Bone/tooth |
AMELX Amelogenesis imperfecta
|
|
No primary system |
Barth syndrome · McLeod syndrome · Smith-Fineman-Myers syndrome · Simpson–Golabi–Behmel syndrome · Mohr–Tranebjærg syndrome · Nasodigitoacoustic syndrome
|
|
|
X-linked dominant
|
|
X-linked hypophosphatemia · Focal dermal hypoplasia · Fragile X syndrome · Aicardi syndrome · Incontinentia pigmenti · Rett syndrome · CHILD syndrome · Lujan–Fryns syndrome · Orofaciodigital syndrome 1
|
|
|
Hematological malignancy/leukemia histology (ICD-O 9590–9989, C81–C96, 200–208)
Lymphoid/Lymphoproliferative, Lymphomas/Lymphoid leukemias (9590–9739, 9800–9839)
|
|
B cell
(lymphoma,
leukemia)
(most CD19, CD20)
|
By development/
marker
|
TdT+
|
ALL (Precursor B acute lymphoblastic leukemia/lymphoma)
|
|
CD5+
|
naive B cell (CLL/SLL)
mantle zone (Mantle cell)
|
|
CD22+
|
Prolymphocytic · CD11c+ (Hairy cell leukemia)
|
|
CD79a+
|
germinal center/follicular B cell (Follicular, Burkitt's, GCB DLBCL, Primary cutaneous follicular lymphoma)
marginal zone/marginal-zone B cell (Splenic marginal zone, MALT, Nodal marginal zone, Primary cutaneous marginal zone lymphoma)
|
|
RS (CD15+, CD30+)
|
Classic Hodgkin's lymphoma (Nodular sclerosis) · CD20+ (Nodular lymphocyte predominant Hodgkin's lymphoma)
|
|
PCDs/PP
(CD38+/CD138+)
|
see immunoproliferative immunoglobulin disorders
|
|
|
By infection
|
KSHV (Primary effusion) · EBV (Lymphomatoid granulomatosis, Post-transplant lymphoproliferative disorder) · HIV (AIDS-related lymphoma) · Helicobacter pylori (MALT lymphoma)
|
|
Cutaneous
|
Diffuse large B-cell lymphoma · Intravascular large B-cell lymphoma · Primary cutaneous marginal zone lymphoma · Primary cutaneous immunocytoma · Plasmacytoma · Plasmacytosis · Primary cutaneous follicular lymphoma
|
|
|
T/NK
|
T cell
(lymphoma,
leukemia)
(most CD3, CD4, CD8)
|
By development/
marker
|
TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma)
prolymphocyte (Prolymphocytic)
CD30+ (Anaplastic large-cell lymphoma, Lymphomatoid papulosis type A)
|
|
Cutaneous
|
MF+variants
|
indolent: Mycosis fungoides · Pagetoid reticulosis · Granulomatous slack skin
aggressive: Sézary's disease · Adult T-cell leukemia/lymphoma
|
|
Non-MF
|
CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma · Pleomorphic T-cell lymphoma · Lymphomatoid papulosis type B
CD30+: CD30+ cutaneous T-cell lymphoma · Secondary cutaneous CD30+ large cell lymphoma · Lymphomatoid papulosis type A
|
|
|
Other peripheral
|
Hepatosplenic · Angioimmunoblastic · Enteropathy-associated T-cell lymphoma · Peripheral T-cell lymphoma-Not-Otherwise-Specified (Lennert lymphoma) · Subcutaneous T-cell lymphoma
|
|
By infection
|
HTLV-1 (Adult T-cell leukemia/lymphoma)
|
|
|
NK cell/
(most CD56)
|
Aggressive NK-cell leukemia · Blastic NK cell lymphoma
|
|
T or NK
|
EBV (Extranodal NK-T-cell lymphoma/Angiocentric lymphoma) · Large granular lymphocytic leukemia
|
|
|
Lymphoid+myeloid
|
Acute biphenotypic leukaemia
|
|
Lymphocytosis
|
Lymphoproliferative disorders (X-linked lymphoproliferative disease, Autoimmune lymphoproliferative syndrome) · Leukemoid reaction · Diffuse infiltrative lymphocytosis syndrome
|
|
|
Cutaneous lymphoid hyperplasia |
Cutaneous lymphoid hyperplasia with bandlike and perivascular patterns · Cutaneous lymphoid hyperplasia with nodular pattern · Jessner lymphocytic infiltrate of the skin
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
Deficiencies of intracellular signaling peptides and proteins
|
|
GTP-binding protein regulators |
GTPase-activating protein
|
Neurofibromatosis type I · Watson syndrome · Tuberous sclerosis
|
|
Guanine nucleotide exchange factor
|
Marinesco–Sjögren syndrome · Aarskog–Scott syndrome · Juvenile primary lateral sclerosis · X-Linked mental retardation 1
|
|
|
G protein |
Heterotrimeic
|
cAMP/GNAS1: Pseudopseudohypoparathyroidism · Progressive osseous heteroplasia · Pseudohypoparathyroidism · Albright's hereditary osteodystrophy · McCune–Albright syndrome
CGL 2
|
|
Monomeric
|
RAS: HRAS (Costello syndrome) · KRAS (Noonan syndrome 3, KRAS Cardiofaciocutaneous syndrome)
RAB: RAB7 (Charcot–Marie–Tooth disease) · RAB23 (Carpenter syndrome) · RAB27 (Griscelli syndrome type 2)
RHO: RAC2 (Neutrophil immunodeficiency syndrome)
ARF: SAR1B (Chylomicron retention disease) ARL13B (Joubert syndrome 8) · ARL6 (Bardet–Biedl syndrome 3)
|
|
|
MAP kinase |
Cardiofaciocutaneous syndrome
|
|
Other kinase/phosphatase |
Tyrosine kinase
|
BTK (X-linked agammaglobulinemia) · ZAP70 (ZAP70 deficiency)
|
|
Serine/threonine kinase
|
RPS6KA3 (Coffin-Lowry syndrome) · CHEK2 (Li-Fraumeni syndrome 2) · IKBKG (Incontinentia pigmenti) · STK11 (Peutz–Jeghers syndrome) · DMPK (Myotonic dystrophy 1) · ATR (Seckel syndrome 1) · GRK1 (Oguchi disease 2) · WNK4/WNK1 (Pseudohypoaldosteronism 2)
|
|
Tyrosine phosphatase
|
PTEN (Bannayan–Riley–Ruvalcaba syndrome, Lhermitte–Duclos disease, Cowden syndrome, Proteus-like syndrome) · MTM1 (X-linked myotubular myopathy) · PTPN11 (Noonan syndrome 1, LEOPARD syndrome, Metachondromatosis)
|
|
|
Signal transducing adaptor proteins |
EDARADD (EDARADD Hypohidrotic ectodermal dysplasia) · SH3BP2 (Cherubism) · LDB3 (Zaspopathy)
|
|
Other |
NF2 (Neurofibromatosis type II) · NOTCH3 (CADASIL) · PRKAR1A (Carney complex) · PRKAG2 (Wolff–Parkinson–White syndrome) · PRKCSH (PRKCSH Polycystic liver disease) · XIAP (XIAP2)
|
|
see also intracellular signaling peptides and proteins
B structural (perx, skel, cili, mito, nucl, sclr) · DNA/RNA/protein synthesis (drep, trfc, tscr, tltn) · membrane (icha, slcr, atpa, abct, othr) · transduction (iter, csrc, itra), trfk
|
|